Literature DB >> 3026080

Immunocompetence of sheep experimentally infected with bovine leukemia virus.

G L Cockerell, A L Parodi, D Levy.   

Abstract

The humoral and cellular immunological reactivity of sheep were studied throughout the first 32 weeks following experimental infection with bovine leukemia virus (BLV). Seroconversion of BLV-inoculated sheep occurred within 4 weeks, but infection was not transmitted to contact control sheep. Despite the persistence of the viral infection, no differences were demonstrated in leukograms, serum IgG concentrations, humoral response to immunization with an irrelevant antigen (rabbit red blood cells), phytomitogen (Concanavalin A and Pokeweek mitogen)-induced lymphocyte blastogenesis, or chemical (1-chloro, 2-4 dinitrobenzene) skin contact hypersensitivity, between BLV-infected and uninfected contact control sheep. These results demonstrate the absence of a nonspecific immunosuppressive effect of BLV and further negate the influence of a generalized immunological deficit on the development of clinical disease in BLV-infected animals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026080     DOI: 10.1016/0165-2427(86)90072-3

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  3 in total

1.  Proviral detection and serology in bovine leukemia virus-exposed normal cattle and cattle with lymphoma.

Authors:  R M Jacobs; Z Song; H Poon; J L Heeney; J A Taylor; B Jefferson; W Vernau; V E Valli
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

2.  T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: relevance to vaccine development.

Authors:  M H Gatei; M F Good; R C Daniel; M F Lavin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

Review 3.  Important mammalian veterinary viral immunodiseases and their control.

Authors:  J R Patel; J G M Heldens; T Bakonyi; M Rusvai
Journal:  Vaccine       Date:  2012-01-17       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.